Use of sulforaphane in COVID-19 : Clinical trials are needed
Copyright © 2022 Elsevier Ltd. All rights reserved..
We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that ais orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.
| Errataetall: |
CommentOn: Mol Immunol. 2021 Dec;140:175-185. - PMID 34717147 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:145 |
|---|---|
| Enthalten in: |
Molecular immunology - 145(2022) vom: 15. Mai, Seite 78-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antioxidants |
|---|
| Anmerkungen: |
Date Completed 14.04.2022 Date Revised 17.12.2022 published: Print-Electronic CommentOn: Mol Immunol. 2021 Dec;140:175-185. - PMID 34717147 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.molimm.2022.03.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338340807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338340807 | ||
| 003 | DE-627 | ||
| 005 | 20231226000442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molimm.2022.03.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338340807 | ||
| 035 | |a (NLM)35303531 | ||
| 035 | |a (PII)S0161-5890(22)00051-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of sulforaphane in COVID-19 |b Clinical trials are needed |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2022 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Mol Immunol. 2021 Dec;140:175-185. - PMID 34717147 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that ais orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19 | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Isothiocyanates |2 NLM | |
| 650 | 7 | |a Sulfoxides |2 NLM | |
| 650 | 7 | |a sulforaphane |2 NLM | |
| 650 | 7 | |a GA49J4310U |2 NLM | |
| 700 | 1 | |a Ramachandram, Dinesh Sangarran |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular immunology |d 1984 |g 145(2022) vom: 15. Mai, Seite 78-79 |w (DE-627)NLM000411434 |x 1872-9142 |7 nnns |
| 773 | 1 | 8 | |g volume:145 |g year:2022 |g day:15 |g month:05 |g pages:78-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.molimm.2022.03.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 145 |j 2022 |b 15 |c 05 |h 78-79 | ||